SCHEMBL1849145

SCHEMBL1849145

CNc1cc(-c2c[nH]nc2-c2c(F)ccc(N(Cc3ccccc3)Cc3ccccc3)c2F)ccn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.34
MAPK14 Q16539 8/20 0.33
MAPK13 O15264 5/20 0.33
MAPK12 P53778 5/20 0.33
MAPK11 Q15759 5/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
CDC42BPB Q9Y5S2 1/20 0.33
ITK Q08881 1/20 0.33
BRAF P15056 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
AAK1 Q2M2I8 1/20 0.31
BUB1 O43683 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31
DYRK1A Q13627 2/20 0.30
DYRK2 Q92630 2/20 0.30
DYRK1B Q9Y463 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1846598 0.88 MAPK14 (0.34) MAPK14MAPK13MAPK12MAPK11BRAF
SCHEMBL1849144 0.84 HRH4 (0.32) BRAF
SCHEMBL1848102 0.83 CYP11B1 (0.34) MAPK14MAPK13MAPK12MAPK11ROCK2
SCHEMBL1847455 0.78 ROCK2 (0.38) PDE10AMAPK14ROCK2ROCK1CDC42BPB
SCHEMBL14143256 0.72 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11ROCK2
SCHEMBL1848383 0.71 CYP2C9 (0.44) BRAFCYP3A4CYP2C9CYP2C19
SCHEMBL4546998 0.70 PIK3C3 (0.37) BRAFCYP3A4CYP2C9CYP2C19
SCHEMBL2478456 0.67 MAPK14 (0.40) MAPK14MAPK13MAPK12MAPK11ROCK2
SCHEMBL1850142 0.66 BRAF (0.48) BRAFKDM4ELMNA
SCHEMBL5353409 0.66 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-01-02 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
EP-2324008-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-25 EP disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 PDE10A 1617/4885MAPK14 55/4885MAPK13 71/4885
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 PDE10A 1617/4885MAPK14 55/4885MAPK13 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.